Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1090-1093

  Coriat, Romain ^a,b   Ropert, Stanislas ^a,b   Mir, Olivier ^a,b   Billemont, Bertrand ^a,b   Chaussade, Stanislas ^a,b   Massault, Pierre Philippe ^a,b   Blanchet, Benoit ^a,b   Vignaux, Olivier ^a,b   Goldwasser, François ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Teaching Hospital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FELODIPINE; SORAFENIB; SUNITINIB; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD DISEASE; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CARCINOMA; CASE REPORT; CAUDA EQUINA SYNDROME; CHRONIC LYMPHOID HEMOPATHY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIBROLAMELLAR CARCINOMA; FOLLOW UP; GENERAL CONDITION DETERIORATION; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; INTESTINE NECROSIS; INTESTINE OBSTRUCTION; INVASIVE CARCINOMA; KIDNEY CARCINOMA; LABORATORY TEST; LIVER METASTASIS; LONG TERM EXPOSURE; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL HISTORY; MONOCLONAL IMMUNOGLOBULINEMIA; PERICARDITIS; PERITONEUM EXUDATE; PHYSICAL EXAMINATION; PNEUMATOSIS INTESTINALIS; PNEUMOPERITONEUM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOSIS; THYROID CARCINOMA; TREATMENT DURATION; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG ANTAGONISM; FATALITY; METABOLISM; MIDDLE AGED; NEOPLASM; RADIOGRAPHY;

ADULT; BENZENESULFONATES; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; PNEUMATOSIS CYSTOIDES INTESTINALIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856074777     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9458-7     Document Type: Article

References (20)

1. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
2. Atkins M, Jones CA, Kirkpatrick P (2006) Sunitinib maleate. Nat Rev 5:279-280
3. Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA (2008) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95-96
4. Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747-1758
5. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
6. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972
7. Steeghs N, Rabelink TJ, Op't Roodt J, et al (2009) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol
8. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860-1869
9. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295-1298
10. Greenstein AJ, Nguyen SQ, Berlin A et al (2007) Pneumatosis intestinalis in adults: management, surgical indications, and risk factors for mortality. J Gastrointest Surg 11:1268-1274
11. St Peter SD, Abbas MA, Kelly KA (2003) The spectrum of pneumatosis intestinalis. Arch Surg 138:68-75
12. Ho LM, Paulson EK, Thompson WM (2007) Pneumatosis intestinalis in the adult: benign to life-threatening causes. Ajr 188:1604-1613
13. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989
14. Mir O, Mouthon L, Alexandre J et al (2007) Bevacizumabinduced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99:85-86
15. Loriot Y, Perlemuter G, Malka D et al (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clinical Practice 5:268-278
16. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559-568
17. Flaig TW, Kim FJ, La Rosa FG et al (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 27:83-87
18. Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621
19. Cacheux W, Boisserie T, Staudacher L et al (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1659-1661
20. Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245